ISPOR - From Proof of Concept to Basis for Initial Marketing Authorization, HTA Appraisal and Reimbursement: Clinical Phase II in the Context of Adaptive Pathways

From Proof of Concept to Basis for Initial Marketing Authorization, HTA Appraisal and Reimbursement: Clinical Phase II in the Context of Adaptive Pathways

Abstract

This article examines the role of phase II in clinical drug development in the context of the adaptive pathways approach.

Authors

Justin Stindt

Full Text

Back to May/June 2016

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now